To include your compound in the COVID-19 Resource Center, submit it here.

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.07 to $1.25 on Friday after FDA accepted for review an NDA resubmission for Adasuve (Staccato loxapine) to treat agitation in patients with schizophrenia or bipolar disorder. The PDUFA date is Feb. 4, 2012. Alexza was up $0.03 last week

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) lost $0.95 (10%) to $8.32 last week after EMA accepted for review an MAA from partner Merck & Co. Inc. (NYSE:MRK) for ridaforolimus to treat metastatic sarcomas. The acceptance triggers a $25 million milestone payment to Ariad, from which Merck has exclusive worldwide rights.

Gentium S.p.A. (NASDAQ:GENT) fell $1.94 (22%) to $6.85 on Thursday after withdrawing an NDA for defibrotide because FDA identified numerous issues with the completeness of the dataset for

Read the full 1204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers